Patent intelligence · US
US 9603853
Formulations of viloxazine
Formulations of viloxazine
Patent details — US 9603853
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 28, 2017
- Expiration
- Mar 23, 2037
- Applicant
- Supernus Pharmaceuticals, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/5375, A61K9/00, A61K9/146
Quick answer
US 9603853 (Formulations of viloxazine) is held by Supernus Pharmaceuticals, Inc.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Supernus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/5375, A61K9/00, A61K9/146, A61K9/2054, A61K9/485
More from Supernus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12121523
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
granted -
US 11911368
Method of treatment of CNS disorders
granted -
US 11896599
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 11638708
Method of treatment of aggression
granted -
US 11458143
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
granted -
US 11351120
Use of higher doses of modified release huperzine formulations
granted -
US 11324753
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
granted -
US 11166960
Modified release preparations containing oxcarbazepine and derivatives thereof
granted
Frequently asked questions
What is US patent 9603853?
US 9603853 (Formulations of viloxazine) is held by Supernus Pharmaceuticals, Inc.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9603853?
Supernus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 68 pharmaceutical patents for this assignee.
When does US 9603853 expire?
Our index shows an expiration date of Mar 23, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.